WO2005007070A3 - Stable pharmaceutical composition - Google Patents

Stable pharmaceutical composition Download PDF

Info

Publication number
WO2005007070A3
WO2005007070A3 PCT/BR2004/000119 BR2004000119W WO2005007070A3 WO 2005007070 A3 WO2005007070 A3 WO 2005007070A3 BR 2004000119 W BR2004000119 W BR 2004000119W WO 2005007070 A3 WO2005007070 A3 WO 2005007070A3
Authority
WO
WIPO (PCT)
Prior art keywords
administration
protease inhibitors
hiv protease
pharmaceutical composition
stable pharmaceutical
Prior art date
Application number
PCT/BR2004/000119
Other languages
French (fr)
Other versions
WO2005007070A2 (en
Inventor
Ogari Pacheco
Elisa Russo
Valter Russo
Original Assignee
Cristalia Prod Quimicos Farm
Ogari Pacheco
Elisa Russo
Valter Russo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Prod Quimicos Farm, Ogari Pacheco, Elisa Russo, Valter Russo filed Critical Cristalia Prod Quimicos Farm
Publication of WO2005007070A2 publication Critical patent/WO2005007070A2/en
Publication of WO2005007070A3 publication Critical patent/WO2005007070A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention describes a soluble and stable pharmaceutical composition for the administration of HIV protease inhibitors. More specifically, the composition comprises a solution of one or two HIV protease inhibitors in a combination of pharmaceutical acceptable organic solvents, a surfactant and a bioavailability enhancer. It is also described a process for preparing concentrate pharmaceutical compositions for the administration of HIV protease inhibitors. The composition of the present invention is suitable to prepare oral solutions for the administration of active drugs and to be encapsulated in hard gelatin capsules or soft gelatin capsules.
PCT/BR2004/000119 2003-07-23 2004-07-19 Stable pharmaceutical composition WO2005007070A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR0302523-3A BR0302523A (en) 2003-07-23 2003-07-23 Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors
BRPI0302523-3 2003-07-23

Publications (2)

Publication Number Publication Date
WO2005007070A2 WO2005007070A2 (en) 2005-01-27
WO2005007070A3 true WO2005007070A3 (en) 2005-03-03

Family

ID=37719699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2004/000119 WO2005007070A2 (en) 2003-07-23 2004-07-19 Stable pharmaceutical composition

Country Status (2)

Country Link
BR (1) BR0302523A (en)
WO (1) WO2005007070A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2012010942A2 (en) 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition

Also Published As

Publication number Publication date
WO2005007070A2 (en) 2005-01-27
BR0302523A (en) 2005-04-05

Similar Documents

Publication Publication Date Title
WO2005065185A3 (en) Temperature-stable formulations, and methods of development thereof
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
WO2005065646A3 (en) Novel drug compositions and dosage forms
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
CO5560580A2 (en) FORMULATIONS OF SUCRALOSE TO DISPENSE FLAVORABLE FLAVORS
HUP0302086A2 (en) Oral pharmaceutical composition with a delayed action and process for its preparation
WO2004016277A3 (en) Extraction of pharmaceutically active cannabinoids from plant materials
MXPA05012821A (en) Pharmaceutical formulation comprising a water-insoluble active agent.
AU2003270255A1 (en) Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve
WO2004078105A3 (en) Fondaparinux sodium composition of high purity, method for production of said composition and pharmaceutical compositions containing the same as active ingredient
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
WO2004032866A3 (en) Therapeutic formulations
WO2001027110A3 (en) Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring
WO2005107709A3 (en) Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
MXPA03010054A (en) Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents.
WO2005007070A3 (en) Stable pharmaceutical composition
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
WO2003092655A3 (en) Use of active ingredient mixtures with azelaic acids and glycyrrhetic acids as anti-acne agents
WO2006034147A3 (en) Compositions and methods for the preparation and administration of poorly water soluble drugs
MXPA05006528A (en) Process for preparing combination pharmaceutical formulations using supercritical fluids.
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
AU2003296602A1 (en) Quaternary compounds comprising propolis as the active substance
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase